CRIS Current Research Information System

CASADEI, BEATRICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.992
EU - Europa 2.293
AS - Asia 1.221
AF - Africa 154
SA - Sud America 11
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.677
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.986
IT - Italia 593
SE - Svezia 473
GB - Regno Unito 427
CN - Cina 423
DE - Germania 316
SG - Singapore 295
VN - Vietnam 281
IN - India 145
IE - Irlanda 111
FR - Francia 78
RU - Federazione Russa 62
TG - Togo 54
CI - Costa d'Avorio 38
ZA - Sudafrica 37
JO - Giordania 34
UA - Ucraina 34
EE - Estonia 30
FI - Finlandia 30
CH - Svizzera 24
NG - Nigeria 24
BG - Bulgaria 23
BE - Belgio 17
NL - Olanda 15
AT - Austria 14
ES - Italia 10
PL - Polonia 10
IR - Iran 7
HK - Hong Kong 6
JP - Giappone 6
PK - Pakistan 6
BR - Brasile 5
CA - Canada 5
CZ - Repubblica Ceca 5
LB - Libano 5
RO - Romania 5
AU - Australia 4
DK - Danimarca 4
HR - Croazia 3
IL - Israele 3
MK - Macedonia 3
MY - Malesia 3
AR - Argentina 2
CL - Cile 2
PE - Perù 2
TR - Turchia 2
BD - Bangladesh 1
BY - Bielorussia 1
EU - Europa 1
GR - Grecia 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
UZ - Uzbekistan 1
Totale 6.677
Salva come PNG Salva come JPEG
Città #
Fairfield 387
Southend 373
Chandler 330
Singapore 262
Ashburn 246
Houston 183
Woodbridge 173
Dong Ket 166
Seattle 156
Wilmington 151
Bologna 138
Princeton 136
Ann Arbor 134
Cambridge 117
Dublin 111
Berlin 62
Santa Clara 60
Lomé 54
Milan 49
Beijing 45
Redmond 43
Nanjing 39
Abidjan 38
Hyderabad 38
New York 38
Westminster 38
Bremen 36
Amman 34
Jinan 34
San Diego 30
Rome 28
Turin 28
Padova 27
Helsinki 24
Abeokuta 23
Bern 21
Boardman 21
Tianjin 19
Changsha 18
Shenyang 18
Brussels 17
Florence 17
Guangzhou 17
Sofia 17
Dearborn 16
Des Moines 14
Hebei 14
Los Angeles 14
Saint Petersburg 14
Olalla 13
Amsterdam 12
Taizhou 12
Jacksonville 11
Jiaxing 11
Catania 10
Hangzhou 10
Nanchang 10
Vienna 10
London 9
Paris 8
Shenzhen 8
Calderara di Reno 7
Norwalk 7
Parma 7
Shanghai 7
Verona 7
Warsaw 7
Wuhan 7
Zhengzhou 7
Adelfia 6
Bühl 6
Chengdu 6
Chicago 6
Hong Kong 6
Lappeenranta 6
Modena 6
Ravenna 6
Redwood City 6
Dongguan 5
Medford 5
Mülheim 5
Tokyo 5
Toronto 5
Vicenza 5
Casalecchio di Reno 4
Cinisello Balsamo 4
Fuzhou 4
Haikou 4
Imola 4
Monmouth Junction 4
Naples 4
Nuoro 4
Nuremberg 4
Phoenix 4
Pune 4
Reggio Emilia 4
Riolo Terme 4
Bari 3
Boydton 3
Chongqing 3
Totale 4.393
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 202
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 187
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 176
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 151
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 148
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 146
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 143
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 142
Dissection of DLBCL Microenvironment Provides a Gene Expression-Based Predictor of Survival Applicable to Formalin-Fixed Paraffin-Embedded Tissue 138
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 136
Constitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphoma 131
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 128
Hairy Cell Leukemia: Allogeneic Transplantation Could be an Optimal Option in Selected Patients. 120
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 120
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 117
Non-hodgkin lymphomas presenting as soft tissue masses: a single center experience and meta-analysis of the published series. 116
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 115
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. 113
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). 112
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 112
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 111
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 110
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 109
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 108
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 108
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 108
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 104
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 102
Impressive Response to Pixantrone after Allogeneic Transplant in a Multiple Relapsed Diffuse Large B-Cell Lymphoma 102
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 102
Vemurafenib mucosal side-effect. 99
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 99
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 95
New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia 94
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: Bridge to transplant 92
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 86
Peripheral blood cellular profile at pre-lymphodepletion is associated with {CD}19-targeted {CAR}-T cell-associated neurotoxicity 84
Erythroderma with brentuximab vedotin (skin side effects in mycosis fungoides) 84
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients. 80
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 80
Erythrodermie mit Brentuximab‐Vedotin (Hautnebenwirkungen bei Mycosis fungoides) 80
Impressive continuous complete response after mogamulizumab in a heavily pretreated Sézary syndrome patient 80
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 79
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 79
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 78
The small molecule CHK1/CHK2 inhibitor PF-0477736 (Pfizer) demonstrates single agent activity in diffuse large B-cell lymphoma 76
null 75
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 69
Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report 65
Case report: Senescence as mechanism of resistance to Pembrolizumab in a Lymphoma patient who failed CD19-Targeted CAR-T cell therapy 64
Successful stem cell harvest and autologous transplantation in a patient with cold agglutinin syndrome and aggressive lymphoma 62
Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas 59
Clinical Response in Heavily Pretreated Mycosis Fungoides with Pembrolizumab: A Case Report 57
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 56
Prolonged responses to brentuximab vedotin as last therapy in Hodgkin lymphoma failing autologous transplantation: A case series 55
Spontaneous remission of follicular lymphoma 54
Frontal predominant encephalopathy with early paligraphia as a distinctive signature of CAR T-cell therapy-related neurotoxicity 52
Long-term efficacy and safety of ibrutinib in the treatment of CLL patients: A real life experience 50
A case of pityriasis lichenoides et varioliformis acuta developed after first dose of Oxford-AstraZeneca COVID-19 vaccine 48
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 48
Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study 45
Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient 42
Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors 39
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study 35
Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report 35
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study 35
Fulminant cerebral edema following CAR T-cell therapy: case report and pathophysiological insights from literature review 34
CAR t-cell therapy in BOlogNa–NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON–NEUTRAL): proposed protocol and results from an Italian study 33
Follicular Lymphoma Microenvironment Traits Associated with Event-Free Survival 32
Therapeutic implications of intratumor heterogeneity for TP53 mutational status in Burkitt lymphoma 31
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 31
Rapid but reversible progression and transformation of chronic lymphocytic leukemia after temporary ibrutinib discontinuation due to off-target toxicity: two interesting cases 30
Intracranial pressure management in fulminant cerebral oedema after CAR T-cell therapy: Not all is lost! 29
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 29
Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers 29
Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation 28
Sequential Double Bridging to Transplant with Diversified Anti- PD1 Monoclonal Antibodies Retreatment in Relapsed Hodgkin Lymphoma: A Case Report 27
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma 26
Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine. 24
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma 24
CAR+ extracellular vesicles predict ICANS in patients with B cell lymphomas treated with CD19-directed CAR T cells 23
Follicular lymphoma: the diminishing role of chemotherapy. 21
Pixantrone as bridging therapy to allogeneic transplantation or in chimeric antigen receptor T‐cell pathway in patients with diffuse large B‐cell lymphoma 20
Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi 19
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy 19
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 18
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 17
Corrigendum: Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue (Annals of Oncology (2018) 29 (2363-2370) DOI: 10.1093/annonc/mdy450) 17
Correction to: Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 16
Gut Microbiota Role in Response to Checkpoint Inhibitor Treatment in Patients with Relapsed/Refractory B-Cell Hodgkin Lymphoma: The MICRO-Linf Study 16
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 15
Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection 15
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 15
Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-cell Lymphoma, Leg-type: A Case Report 15
Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy 14
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study 14
Mogamulizumab-associated rashes, their presentation and prognostic significance: a single-centre retrospective case series analysis 13
Endobronchial Presentation of Hodgkin Lymphoma Responding to Pembrolizumab: A Case Report 12
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study 11
Totale 6.944
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.727
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.727
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.160 0 0 0 58 167 150 169 185 197 102 55 77
2020/2021794 107 46 25 15 14 16 22 39 106 44 43 317
2021/20221.226 121 56 59 106 97 62 23 93 44 118 270 177
2022/20231.678 142 223 117 202 124 125 55 138 260 53 129 110
2023/2024739 56 98 67 88 64 90 37 54 24 66 39 56
2024/2025850 169 322 299 60 0 0 0 0 0 0 0 0
Totale 6.944